Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-centre Study to Evaluate the Long-term Safety and Tolerability of REN001 in Subjects With Primary Mitochondrial Myopathy (PMM)

X
Trial Profile

An Open-label, Multi-centre Study to Evaluate the Long-term Safety and Tolerability of REN001 in Subjects With Primary Mitochondrial Myopathy (PMM)

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 30 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavodelpar (Primary)
  • Indications Mitochondrial myopathies
  • Focus Adverse reactions; Registrational
  • Acronyms STRIDE AHEAD
  • Sponsors Reneo Pharmaceuticals
  • Most Recent Events

    • 07 Feb 2024 Status changed from recruiting to discontinued.
    • 12 Jan 2024 This trial has been discontinued in Denmark (Global end date: 14 Dec 2023).
    • 10 Jan 2024 This trial has been discontinued in Hungary (Global end date: 14 Dec 2023).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top